{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:55:41Z","timestamp":1790103341599,"version":"4.0.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.ucl.2020.04.005","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T22:33:20Z","timestamp":1591914800000},"page":"281-291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Imaging for Metastatic Renal Cell Carcinoma"],"prefix":"10.1016","volume":"47","author":[{"given":"Soumya V.L.","family":"Vig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elcin","family":"Zan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella K.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ucl.2020.04.005_bib1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4161\/cbt.9.1.10340","article-title":"CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies.","volume":"9","author":"Nathan","year":"2010","journal-title":"Cancer Biol Ther"},{"issue":"4","key":"10.1016\/j.ucl.2020.04.005_bib2","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0094-0143(03)00056-9","article-title":"Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease","volume":"30","author":"Janzen","year":"2003","journal-title":"Urol Clin North Am"},{"issue":"2","key":"10.1016\/j.ucl.2020.04.005_bib3","doi-asserted-by":"crossref","first-page":"360","DOI":"10.2214\/AJR.07.2077","article-title":"Imaging in metastatic renal cell carcinoma","volume":"189","author":"Griffin","year":"2007","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"10.1016\/j.ucl.2020.04.005_bib4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4103\/1450-1147.150535","article-title":"Clinical effectiveness of (18)F-fluorodeoxyglucose positron emission tomography\/computed tomography in management of renal cell carcinoma: a single institution experience","volume":"14","author":"Win","year":"2015","journal-title":"World J Nucl Med"},{"issue":"6","key":"10.1016\/j.ucl.2020.04.005_bib5","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.rcl.2017.06.007","article-title":"Imaging and screening of kidney cancer","volume":"55","author":"Diaz de Leon","year":"2017","journal-title":"Radiol Clin North Am"},{"key":"10.1016\/j.ucl.2020.04.005_bib6","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1200\/EDBK_158892","article-title":"The Evolution of Systemic Therapy in Metastatic Renal Cell Carcinoma","volume":"35","author":"Hutson","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"10.1016\/j.ucl.2020.04.005_bib7","article-title":"Immunotherapy for advanced renal cell cancer","author":"Coppin","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"21","key":"10.1016\/j.ucl.2020.04.005_bib8","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1001\/jama.295.21.2516","article-title":"Sunitinib in patients with metastatic renal cell carcinoma","volume":"295","author":"Motzer","year":"2006","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ucl.2020.04.005_bib9","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/1756287215597647","article-title":"Targeting PD-1\/PD-L1 in the treatment of metastatic renal cell carcinoma","volume":"7","author":"Weinstock","year":"2015","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.ucl.2020.04.005_bib10","doi-asserted-by":"crossref","unstructured":"Motzer J, Thomas Powles, Michael B. Atkins, et\u00a0al. IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology, 2018;36(6_suppl):578.","DOI":"10.1200\/JCO.2018.36.6_suppl.578"},{"issue":"4","key":"10.1016\/j.ucl.2020.04.005_bib11","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.2214\/AJR.07.3568","article-title":"Renal cell carcinoma: diagnosis, staging, and surveillance","volume":"191","author":"Ng","year":"2008","journal-title":"AJR Am J Roentgenol"},{"issue":"6","key":"10.1016\/j.ucl.2020.04.005_bib12","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.2214\/AJR.11.8381","article-title":"Imaging in the follow-up of renal cell carcinoma","volume":"198","author":"Patel","year":"2012","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.ucl.2020.04.005_bib13","doi-asserted-by":"crossref","first-page":"648495","DOI":"10.1155\/2015\/648495","article-title":"Magnetic resonance imaging as a biomarker for renal cell carcinoma","volume":"2015","author":"Wu","year":"2015","journal-title":"Dis Markers"},{"issue":"5","key":"10.1016\/j.ucl.2020.04.005_bib14","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.eururo.2019.02.011","article-title":"EAU oncology guidelines for renal cell carcinoma","volume":"75","author":"Ljungberg","year":"2019","journal-title":"Eur Assoc Urol"},{"issue":"3","key":"10.1016\/j.ucl.2020.04.005_bib15","first-page":"520","article-title":"Renal mass and localized renal cancer: AUA guideline","volume":"198","author":"Campbell","year":"2017","journal-title":"J\u00a0Urol"},{"issue":"5","key":"10.1016\/j.ucl.2020.04.005_bib16","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jacr.2016.01.021","article-title":"ACR Appropriateness Criteria Renal Cell Carcinoma Staging.","volume":"13","author":"Vikram","year":"2016","journal-title":"J\u00a0Am Coll Radiol"},{"issue":"6","key":"10.1016\/j.ucl.2020.04.005_bib17","first-page":"2126","article-title":"The diagnostic value of bone scan in patients with renal cell carcinoma","volume":"166","author":"Koga","year":"2001","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.ucl.2020.04.005_bib18","first-page":"146","article-title":"[Positron emission tomography in diagnosis of renal cell carcinoma]","volume":"35","author":"Bachor","year":"1996","journal-title":"Urologe A"},{"issue":"5","key":"10.1016\/j.ucl.2020.04.005_bib19","first-page":"1806","article-title":"Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma","volume":"171","author":"Kang","year":"2004","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.ucl.2020.04.005_bib20","doi-asserted-by":"crossref","first-page":"230.e5-6","DOI":"10.1016\/j.urology.2007.11.134","article-title":"Solitary liver metastasis of chromophobe renal cell carcinoma 20 years after nephrectomy treated by hepatic resection","volume":"72","author":"Lordan","year":"2008","journal-title":"Urology"},{"issue":"Suppl 1","key":"10.1016\/j.ucl.2020.04.005_bib21","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.3747\/co.v16i0.417","article-title":"Role of cytokine therapy for renal cell carcinoma in the era of targeted agents","volume":"16","author":"Koneru","year":"2009","journal-title":"Curr Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2020.04.005_bib22","doi-asserted-by":"crossref","first-page":"W282","DOI":"10.2214\/AJR.14.13236","article-title":"RECIST 1.1 compared with RECIST 1.0 in patients with advanced renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy","volume":"204","author":"Krajewski","year":"2015","journal-title":"AJR Am J Roentgenol"},{"issue":"6","key":"10.1016\/j.ucl.2020.04.005_bib23","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.2214\/AJR.17.18018","article-title":"Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients With Metastatic Renal Cell Carcinoma Who Are Receiving Salvage Therapy","volume":"209","author":"Kang","year":"2017","journal-title":"AJR Am J Roentgenol."},{"key":"10.1016\/j.ucl.2020.04.005_bib24","first-page":"1","article-title":"Thorsten Persigehl, RECIST 1.1, irRECIST 1.1, and mRECIST: how to do","volume":"4","author":"Joern Henze","year":"2016","journal-title":"Curr Radiol Rep"},{"issue":"suppl 2","key":"10.1016\/j.ucl.2020.04.005_bib25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1634\/theoncologist.13-S2-4","article-title":"Response evaluation of gastrointestinal stromal tumors","volume":"13","author":"Choi","year":"2008","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.ucl.2020.04.005_bib26","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/sj.bjc.6605567","article-title":"Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib","volume":"102","author":"Van der Veldt","year":"2010","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ucl.2020.04.005_bib27","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2214\/AJR.09.2941","article-title":"Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT","volume":"194","author":"Smith","year":"2010","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.ucl.2020.04.005_bib28","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s00259-014-2766-y","article-title":"68Ga-PSMA PET\/CT imaging of metastatic clear cell renal cell carcinoma","volume":"41","author":"Demirci","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ucl.2020.04.005_bib29","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-Update and clarification: From the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ucl.2020.04.005_bib30","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.urology.2007.03.025","article-title":"Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms","volume":"70","author":"Baccala","year":"2007","journal-title":"Urology"},{"issue":"10","key":"10.1016\/j.ucl.2020.04.005_bib31","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s12149-015-1017-z","article-title":"Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted (1)(8)F-DCFPyL PET\/CT","volume":"29","author":"Rowe","year":"2015","journal-title":"Annals of nuclear medicine"},{"issue":"2","key":"10.1016\/j.ucl.2020.04.005_bib32","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2214\/AJR.14.12490","article-title":"PET\/CT with (124)I-cG250: great potential and some open questions","volume":"203","author":"Khandani","year":"2014","journal-title":"AJR Am J Roentgenol"},{"issue":"4","key":"10.1016\/j.ucl.2020.04.005_bib33","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S1470-2045(07)70044-X","article-title":"Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial","volume":"8","author":"Divgi","year":"2007","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2020.04.005_bib34","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.2011.41.2445","article-title":"Positron emission tomography\/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial","volume":"31","author":"Divgi","year":"2013","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014320300203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014320300203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:37:32Z","timestamp":1758807452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014320300203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0094014320300203"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2020.04.005","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Imaging for Metastatic Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2020.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}